



SUZANO

Joint Venture with Kimberly-Clark

SUZB
B3 LISTED NM

SUZ
LISTED
NYSE


Disclaimer

This presentation contains what are considered “forward-looking statements,” as defined in Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act, as amended. Some of these forward-looking statements are identified with words such as “believe,” “may,” “could,” “would,” “possible,” “will,” “should,” “expect,” “intend,” “plan,” “anticipate,” “estimate,” “potential,” “outlook” or “continue,” as well as the negative forms of these words, other terms of similar meaning or the use of future dates.

The forward-looking statements include, without limitation, statements related to the declaration or payment of dividends, implementation of the key operational and financial strategies and investment plans, guidance about future operations and factors or trends that influence the financial situation, liquidity or operational results. Such statements reflect the current view of the management and are subject to diverse risks and uncertainties. These are qualified in accordance with the inherent risks and uncertainties involving future expectations in general, and actual results could differ materially from those currently anticipated due to various risks and uncertainties. There is no guarantee that the expected events, trends or results will actually occur. The statements are based on diverse assumptions and factors, including general economic and market conditions, industry conditions and operating factors. Any changes in such assumptions or factors could cause actual results to differ materially from current expectations. Suzano does not undertake any obligation to update any such forward-looking statements as a result of new information, future events or otherwise, except as expressly required by law. All forward-looking statements in this presentation are covered in their entirety by this disclaimer.

In addition, this presentation contains some financial indicators that are not recognized by the BR GAAP or IFRS. These indicators do not have a standard meaning and may not be comparable to indicators with a similar description used by other companies. We provide these indicators because we use them as measurements of Suzano's performance; they should not be considered separately or as a replacement for other financial metrics that have been disclosed in accordance with BR GAAP or IFRS.

Creation of a Joint Venture, in which Suzano will have control



Rationale for Suzano & K-C Partnership

- ✓ Combination of **industrial and operational excellence + commercial and branding expertise**
- ✓ JV Structure grants **operational continuity and aligns to capture efficiency gains**
- ✓ **Successful track record** of integrating Suzano and K-C operations in Brazil
- ✓ Companies share **values and strong culture based on innovation and sustainability**
- ✓ **Accelerating fiber-to-fiber strategy** in the global tissue market

M&A Assumptions

Transaction Attributes

Value creation

✓ Expected IRR of 15.5% (US\$ nominal terms)

Scalability

✓ Potential to lead fiber-to-fiber movement across regions and create a new reference

✓ 8th largest tissue player globally

Competitiveness

✓ Iconic brands with price premium and high-quality asset base

Higher operational efficiency and/or synergies

✓ Efficiency gains expected to be captured within 3 years (US\$175M p.a.¹)

Investment Grade rating status

✓ Limited impact on leverage with cash flow volatility reduction

1. Running rate considering 100% capture from the 3rd year onwards.

Joint Venture NewCo: Business overview

Main figures



1.0 Mt
Tissue Total
Capacity



~ US\$3.3 bn
Pro forma
Net Revenues¹



~ US\$0.5 bn
Pro forma
Adj. EBITDA¹



~ 9,000
Employees

Operations



22 mills
in 14 countries



70+ countries
with sales



2 business segments
Family Care
& **Professional**

Footprint

Mills locations

EMEA
(Europe, the Middle
East and Africa)

Italy, France, United
Kingdom, Germany,
Spain, Israel and
South Africa


APAC
(Asia-Pacific)

Australia, Malaysia,
Thailand and
Taiwan

**Central and
South
America**

El Salvador, Peru
and Colombia


Revenues by region²



■ EMEA ■ UK ■ LatAm ■ Asia ■ Oceania

1. Pro forma net revenues and adjusted EBITDA 2024 consider non-recurring effects and JV business scope adjustments. 2. Based on 2024 figures.


A portfolio of leading brands across attractive categories




Adequate return and profitability with higher operational efficiency

Expected unleveraged IRR in US\$ nominal terms	Potential operational gains ¹
15.5%	US\$175 million p.a.

Potential operational gains breakdown²:



K-C's acquired assets in Brazil³ - Mogi mill case



(Operational gains based on Jan-May 2023 and Jan-May-2025 figures)

1. Running rate considering 100% capture from the 3rd year onwards. 2. Preliminary estimates and subject to adjustments based on future assessment. 3. Material Fact June 1st 2023. 4. Does not include pulp price change.


Downstream integration reduces Suzano's cash flow volatility and diversifies portfolio




Net revenue by segment¹

FY 2024, %

Consumer Goods Paper and Packaging Pulp




Suzano As-Is




Suzano + JV (100%)
Pro Forma

EBITDA by segment²

FY 2024, %



Suzano As-Is




Suzano + JV (100%)
Pro Forma


Net revenue by region¹

FY 2024, %

Europe Asia Brazil North America LATAM (ex-Brazil) Other³



Suzano As-Is




Suzano + JV (100%)
Pro Forma

Notes:

- (1) Converted by the average dollar for the period (2024 = FX@5.39).
- (2) The share of Suzano's Consumer Goods segment (As-Is) consider pulp at cost according to 2024 Financial Statements. Pro Forma EBITDA of the joint venture considers pulp at market price. Includes 100% of JV's EBITDA.
- (3) Oceania, Middle East and Africa.

Pathway from Signing to Closing





Investor Relations
ir.suzano.com.br
ri@suzano.com.br

Q&A

SUZB
B3 LISTED NM

SUZ
LISTED
NYSE